Intraday Info: NanoString Technologies Inc (NASDAQ:NSTG) locked on 06/02/2017 at $18.80. It has average volume 187.67k whilst it totals volume 140,600. The company has EPS -2.25 and according to analysts next quarter EPS and next year estimate EPS will -0.49 and -2.07 respectively. Profit Margin of NSTG -53.00% and it total income 44.30 million.
Ownership Summary: NanoString Technologies Inc has total institutional ownership 83.00% while its total outstanding shares 21 millions that’s value of holdings $333 million.
Active Positions: In the latest year, NSTG 71 holders have raised its positions while it contains total 2,579,312 shares. And the strength of reduced positions holders and held positions holders are 24 and 17 respectively.
New and Sold Out Positions: In NSTG force of new positions holders 31 and it has total shares 1,009,513. And force of sold out positions holders 7 and it has 732,473 shares.
Comparison with Other Company: The Market Value of NSTG is $394,875 below from Seattle Genetics, Inc. market value which is $8M. Current Last Sale of NSTG is $18.8 below from SGEN current last sale which is $61.54.
NanoString technologies, Inc. offers nSolver evaluation software, a software that assists researchers to check, normalize, and analyze their statistics; and nCounter dash Profiler, an instrument that provides liquid managing steps and virtual evaluation through a microfluidic cartridge. in addition, it presents Pan cancer pathways gene expression panels, immune profiling gene expression panels, progression panels, RNA, and profiles, in addition to other gene expression, microRNA expression, and most cancers replica quantity version panels; custom CodeSets; nCounter elements reagents that permit users to layout custom designed assays for gene expression, copy wide variety variant, and gene fusions; and nCounter grasp kits that consist of ancillary reagents and plasticware to setup and method samples within the nCounter Prep Station and nCounter virtual Analyzer. It markets its structures and related consumables to researchers in academic, government, and biopharmaceutical laboratories, similarly to to clinical laboratories and clinical centers. NanoString technology, Inc. has partnershipwith Celgene agency; Merck Sharp & Dohme Corp; Medivation, Inc.; and Astellas Pharma, Inc, further to has collaborations with diverse biopharma corporations to increase diagnostic exams for various most cancers treatments.